A Study in Participants With Non-cirrhotic NASH With Fibrosis
Public ClinicalTrials.gov record NCT05638737. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Pharmacodynamics of AZD4831 (Mitiperstat) in Participants With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) With Fibrosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial. Participants will be in the trial for up to 24 weeks, including a screening period lasting up to 8 weeks, a 12-week treatment period, and a 4-week safety follow-up period Participants are not expected to directly benefit from treatment during this trial. Participants will help researchers learn more about and how to develop AZD4831 to treat NASH.
Study identification
- NCT ID
- NCT05638737
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 112 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 25, 2022
- Primary completion
- Apr 3, 2024
- Completion
- Apr 3, 2024
- Last update posted
- Jul 8, 2025
2022 – 2024
United States locations
- U.S. sites
- 17
- U.S. states
- 7
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Chandler | Arizona | 85224 | — |
| Research Site | Tucson | Arizona | 85712 | — |
| Research Site | Chula Vista | California | 91911 | — |
| Research Site | Montclair | California | 91763 | — |
| Research Site | Orange | California | 92868 | — |
| Research Site | Redondo Beach | California | 90277 | — |
| Research Site | Stanford | California | 94305 | — |
| Research Site | Jacksonville | Florida | 32256 | — |
| Research Site | Lakeland | Florida | 33803 | — |
| Research Site | Lakeland | Florida | 33813 | — |
| Research Site | Miami | Florida | 33135 | — |
| Research Site | Las Vegas | Nevada | 89109 | — |
| Research Site | Yonkers | New York | 10701 | — |
| Research Site | Morehead City | North Carolina | 28557 | — |
| Research Site | Dallas | Texas | 75230 | — |
| Research Site | Houston | Texas | 77090 | — |
| Research Site | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05638737, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 8, 2025 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05638737 live on ClinicalTrials.gov.